At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 60 enrolled
Drug / intervention
Aspirin +2 moredrug
Likely dose
Aspirin 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Aspirin as Adjuvant Therapy in Young Psychotic Patients
Clinic for Psychiatric Disorders, Dr Laza Lazarevic·interventional·Posted Feb 19, 2016·Updated Sep 23, 2024
In Brief
A Phase 3 clinical trial evaluating Aspirin, Placebo, and 1 other intervention for Psychosis and 2 related conditions. Completed, enrolled 60 participants across 1 site.
Detailed Summary
In this double blind randomized clinical trial the investigators are going to exam influence of adjuvant Aspirin therapy on soft neurological signs (Heidelberg scale), positive and negative symptoms (PANSS), cytokine profile and inflammatory factors, as well as on cognition (MoCA) in young psychotic patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsychosis, Acute Psychosis, Schizophrenia
CountriesSerbia
CollaboratorsStanley Medical Research Institute
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartJul 2017
Primary CompletionDec 2019
TodayJul 2026
First PostedFeb 19, 2016
Enrollment StartJul 20, 2017
Primary CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.4 years ago
Interventions
Aspirindrug
1000 mg pd in two doses
Placebodrug
two pills twice a day (instead of aspirin and pantoprazole)
Pantoprazoledrug
Pantoprazole 40 mg/pd in two doses, for gastric protection